safety of bca101, an egfr/tgfβ inhibitor, with pembrolizumab in hnscc
Published 1 year ago • 108 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
2:26
sd-101 plus pembrolizumab for hnscc
-
0:55
dr. cohen on immunotherapy in head and neck squamous cell carcinoma
-
11:47
pembrolizumab in hnscc
-
10:09
diagnosis, staging, and prognosis
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
1:20
comparing petosemtamab and pembrolizumab in hnscc with existing therapies
-
1:05
rationale for evaluating sting agonists in head and neck cancer
-
1:05
dr. succaria on combination immunotherapy in head and neck cancer
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
9:40
emerging agents to treat hnscc
-
1:53
targeting galectin-1 with radiation and immune checkpoints in head and neck cancer
-
1:52
esmo 2022 highlights in head and neck cancer
-
0:51
dr. machiels on pembrolizumab and chemoradiation in hnscc
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
1:56
dr. weiss on the role of immunotherapy in head and neck cancer
-
1:34
rationale for targeting galectin-1 in head and neck cancer
-
6:36
surgical management of hnscc